Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus chemotherapy as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma
CTR20230810Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Started May 2023; status: active.
02
Drugs
cadonilimab
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20230810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230810.